Seed · Biotech · Copenhagen, Denmark · Founded 2025 · 11–50 employees
Skape Bio is an early-stage biotechnology startup that develops de novo designed miniprotein therapeutics targeting G protein-coupled receptors (GPCRs), a vital but historically challenging family of drug targets. The company combines AI-guided protein design originating out of Nobel Laureate David Baker's lab with high-throughput screening directly in living human cells and translational pharmacology. Its goal is to create a new therapeutic class of compact, stable, and highly selective agonists/antagonists to treat complex diseases across oncology, inflammation, metabolic disease, and neurology. In April 2026, the company was selected as part of the Mission BioCapital Platinum Program, securing a pre-seed ticket investment of up to $500,000.
No open roles listed right now.